Tumor markers tests are diagnostic tools designed to detect specific substances in the blood, urine, or tissues that may indicate the presence of cancer or monitor its progression. These tests measure proteins, hormones, genetic mutations, or other biomolecules associated with various types of tumors. Tumor markers are used for early screening, diagnosis, prognosis assessment, treatment monitoring, and recurrence detection.
Common tumor markers include:
AFP (Alpha-Fetoprotein) – for liver and germ cell cancers
CEA (Carcinoembryonic Antigen) – for colorectal, lung, and breast cancers
CA 125 – for ovarian cancer
PSA (Prostate-Specific Antigen) – for prostate cancer
CA 19-9 – for pancreatic and gastrointestinal cancers
HER2/neu & BRCA mutations – for breast and ovarian cancers
These tests are performed using advanced immunoassay techniques (e.g., ELISA, CLIA, ECLIA) or molecular diagnostics (PCR, NGS). Some tests are combined with imaging or biopsy for higher accuracy.
Tumor marker tests are minimally invasive, typically requiring only a blood sample, and provide rapid results. They play a crucial role in personalized medicine, helping clinicians tailor treatment plans based on biomarker profiles. However, they are not standalone diagnostic tools and are used alongside other clinical evaluations for comprehensive cancer management.
| Tumor Markers Test 肿瘤标志物检测 | |||
| AFP Alpha Fetoprotein Test Cassette | WB/S/P | Cassette | 25T |
| CEA Carcinoma Embryonic Ag Test Cassette | WB/S/P | Cassette | 25T |
| FOB Fecal Occult Blood Test Cassette | Feces | Cassette | 20T |
| PSA Prostate Specific Ag Test Cassette | WB/S/P | Cassette | 25T |
| AFP/CEA/PSA Test Panel | WB/S/P | Panel | 20T |
| TF Transferrin Test Cassette | Feces | Cassette | 25T |
| Hemoglobin (Hb)/Transferrin (TF) Test Panel | Feces | Panel | 20T |
Preparation
Patient Preparation: Inform the patient that fasting may be required (depending on the marker). Avoid strenuous exercise before the test.
Sample Type: Confirm whether the test requires blood, urine, or tissue samples (commonly serum or plasma for blood tests).
Materials Needed: Collect sterile tubes (e.g., serum separator tubes), needles, alcohol swabs, labels, and a biohazard container.
Sample Collection
Blood Sample: Clean the venipuncture site with alcohol, draw 3-5 mL of blood into the tube, and invert gently to mix with anticoagulant (if needed).
Urine Sample: Collect midstream urine in a sterile container (for markers like BTA or UBC).
Tissue Sample: For biopsies, follow sterile procedures and place samples in formalin or as required.
Sample Handling
Centrifuge blood samples at 3000 rpm for 10 minutes to separate serum/plasma.
Label samples clearly with patient details and store at 2-8°C if not tested immediately (freeze at -20°C for long-term storage).
Testing Procedure
Automated Immunoassay: Load samples into the analyzer (e.g., ELISA, CLIA, or EIA systems) and select the tumor marker test (e.g., PSA, CA 125, CEA).
Manual Testing: Add samples to wells coated with antibodies, incubate, wash, and measure absorbance/fluorescence.
Result Interpretation
Compare values with reference ranges (e.g., PSA <4 ng/mL for men).
High levels may indicate malignancy but require further diagnostic confirmation (imaging, biopsy).
Post-Test Steps
Dispose of used materials in biohazard waste.
Document results in the patient’s file and consult a physician for clinical correlation.
High Accuracy and Sensitivity – Tumor marker tests utilize advanced immunoassay or molecular techniques to detect specific biomarkers associated with cancers, ensuring precise and early identification of malignant conditions.
Wide Range of Detectable Markers – The tests cover various tumor markers such as AFP (liver cancer), CA 125 (ovarian cancer), PSA (prostate cancer), CEA (colorectal cancer), and CA 19-9 (pancreatic cancer), enabling multi-cancer screening.
Non-Invasive or Minimally Invasive – Most tumor marker tests require only a blood sample, reducing patient discomfort compared to biopsies or imaging procedures.
Early Cancer Detection – These tests help identify cancer at early stages, even before symptoms appear, improving treatment outcomes and survival rates.
Monitoring Treatment Efficacy – Tumor marker levels are tracked over time to assess the effectiveness of chemotherapy, radiation, or surgery, allowing for timely adjustments in therapy.
Detection of Recurrence – Regular testing can signal cancer recurrence earlier than imaging scans, enabling prompt intervention.
Automated and Rapid Processing – Modern tumor marker tests use automated analyzers, delivering fast and reliable results within hours.
Customizable Panels – Clinicians can order individual markers or comprehensive panels based on patient risk factors (e.g., family history, genetic predisposition).
High Specificity with Low False Positives – Advanced assays minimize cross-reactivity with non-cancerous conditions, reducing unnecessary follow-up tests.
Cost-Effective Screening Tool – Compared to imaging or biopsies, tumor marker tests offer a more affordable option for initial cancer screening and monitoring.
Compatibility with Other Diagnostics – Results can be combined with imaging, biopsies, or liquid biopsies for a more accurate diagnosis.
Personalized Medicine Support – Some markers (e.g., HER2/neu, BRCA) guide targeted therapy and immunotherapy selection.
Portable Point-of-Care Options – Emerging rapid tests allow for decentralized testing in clinics or remote settings.
Research and Drug Development Use – Tumor marker assays aid in clinical trials by evaluating new anticancer drugs' biological effects.
Hospital Oncology Departments
Cancer Diagnostic Laboratories
Early Disease Screening Clinics
Medical Research Institutions
Primary Care Facilities
Specialized Treatment Centers
Want to Get More Details About JCMED Medical Consumables?
We're waiting for your contact!